BridgeBio Neutral Stance From Citi Shakes ATTR-CM Outlook
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
Strengths include clarity and control, while weaknesses may involve complexity and time to maintain across life changes.
28,655 articlesCiti initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
A 2026 market backdrop prompts a fresh look at when to retire early. A saver chasing seven figures weighs the 4% rule...
Micron Technology is at a pivotal moment as AI-related demand collides with a cyclical memory market. Shares have sur...
Goldman Sachs expands its US Conviction List with four new names pegged for double-digit upside, signaling a continue...
A pair of geopolitical developments is reviving appetite for riskier assets and triggering a chip-stock rally back fu...
Johnson & Johnson shares jump as the company pushes through a resilient oncology lineup and strategic investments, li...
If you’re worried about stock market volatility, a proven dividend stock can be your anchor. This guide explains why ...
High earners are pursuing a legal workaround—backdoor roth 401(K) conversions—to move after-tax 401(K) money into Rot...
Oil market swings in early 2026 pushed Exxon Mobil and ConocoPhillips to diverging paths. This piece analyzes who is ...
June retail sales rose modestly, led by auto purchases and a surge in online spending during Prime Day-like promotion...
For more than a decade, one Vanguard ETF quietly outpaced the broad market. This article dives into why its growth ti...
Nexa Lending’s Loren Riddick outlines how policy reform could reshape the HECM program, addressing reverse-to-reverse...